--- /home/parlparse/parldata/cmpages/wrans/answers2005-10-13b.html	2007-01-21 05:46:45.000000000 +0000
+++ /home/parlparse/parldata/tmp/patchtmp-answers2005-10-13b-vUS_bY.html	2007-06-02 00:07:20.000000000 +0100
@@ -5802,13 +5802,13 @@
 
 
 <p><a name="qn_112"><a name="51013w14.html_wqn5"><b> Mrs. Iris Robinson: </b> 
- To ask the Secretary of State for Northern Ireland (1) what the implications are for dementia sufferers in Northern Ireland of the National Institute for Health and Clinical Excellence recommendation that certain dementia medications should no longer be available through the NHS; and if he will make a statement.  [17597]
+ To ask the Secretary of State for Northern Ireland what the implications are for dementia sufferers in Northern Ireland of the National Institute for Health and Clinical Excellence recommendation that certain dementia medications should no longer be available through the NHS; and if he will make a statement.  [17597]
 
 </p>
 
 
 
-<p><a name="qnpa_8">The National Institute for Health and Clinical Excellence is reviewing its 2001 appraisal of medicines for the treatment of Alzheimer&#039;s disease. As part of this review, the Institute has produced, and consulted on, draft preliminary recommendations that the drugs donepezil, rivastigmine, galantamine and memantine should not be routinely used in treating new patients in the NHS. Following consultation, the institute has deferred publication of its final guidance on these drugs until early next year.
+<p><a name="qnpa_8"><b>Mr. Woodward:</b> The National Institute for Health and Clinical Excellence is reviewing its 2001 appraisal of medicines for the treatment of Alzheimer&#039;s disease. As part of this review, the Institute has produced, and consulted on, draft preliminary recommendations that the drugs donepezil, rivastigmine, galantamine and memantine should not be routinely used in treating new patients in the NHS. Following consultation, the institute has deferred publication of its final guidance on these drugs until early next year.
 
 
 
@@ -5825,7 +5825,8 @@
 
 
 
-<p><a name="qnpa_9">(2) what clinical guidance on dementia medications has been provided by the clinical resource efficiency support team.  [17598]</p>
+<p><a name="qnpa_9"><b>Mrs. Iris Robinson:</b>
+ To ask the Secretary of State for Northern Ireland what clinical guidance on dementia medications has been provided by the clinical resource efficiency support team.  [17598]</p>
 
 
 
